FDA announces recall of more than 32 million disposable syringes

Cardinal Health is recalling more than 32 million disposable syringes, according to a new alert from the U.S. Food and Drug Administration (FDA). This is a Class I recall, which means the FDA believes using these products “may cause serious injuries or death.”

The company first started distributing its Cardinal Health Monoject syringes in June 2023. Compared to the Covidien Monoject syringes, however, these newer products were designed with different dimensions that are causing ongoing issues with syringe pumps. According to the FDA, these different dimensions “may result in pump performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms.”

Cardinal Health recalled syringes

As pictured above, the Covidien Monoject syringe on the left has different dimensions than the Cardinal Health Monoject syringe on the right. Image and caption courtesy of the FDA.

The recall includes a total of 32.43 million disposable syringes distributed from June to August 2023. A full list of product names and product codes is available on the FDA’s advisory.

Cardinal Health has received 15 reports of therapy being delayed due to this issue. There have been another 13 reports of inaccurate volume/rate dispensing.

The FDA emphasized that this is not necessarily a correction, it is a warning that the Cardinal Health Monoject syringes should not be used with syringe infusion pumps.

The Covidien-branded Monoject syringes can still be used with syringe infusion pumps if customers still have those on hand.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.